Use of low molecular weight dermatan sulfate for the manufacture of a medicament for the prevention and therapy of the pulmonary embolism

摘要

The invention refers to the prevention and therapy of the pulmonary embolism with pharmaceutical compositions containing low molecular weight dermatan sulfate. These pharmaceutical compositions are administered by subcutaneous, intramuscular or intravenous route at a daily dosage between 200 and 3000 mg of active principle.;The low molecular weight dermatan sulfate preferred in carrying out the invention has an average molecular weight equal to 5500±1100 Daltons and is obtained by depolymerization of the dermatan sulfate of natural origin in the presence of hydrogen peroxide and cupric ions.